American International Group, Inc. Adagio Therapeutics, Inc. Transaction History

American International Group, Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	N/A	494 Added 2.03%	24,776 $82,000
Q4 2022 Feb 10, 2023	SELL	$3.08 - $4.05 $274 - $360	-89 Reduced 0.37%	24,282 $80,000
Q3 2022 Nov 14, 2022	BUY	$2.97 - $4.83 $1,021 - $1,661	344 Added 1.43%	24,371 $76,000
Q2 2022 Aug 12, 2022	SELL	$2.54 - $4.52 $13,215 - $23,517	-5,203 Reduced 17.8%	24,027 $79,000
Q1 2022 May 13, 2022	BUY	$3.81 - $10.77 $68,595 - $193,903	18,004 Added 160.38%	29,230 $133,000
Q4 2021 Feb 11, 2022	SELL	$6.35 - $47.04 $2,133 - $15,805	-336 Reduced 2.91%	11,226 $82,000
Q3 2021 Nov 12, 2021	BUY	$20.88 - $56.08 $241,414 - $648,396	11,562 New	11,562 $488,000

63.9M

2.3K

2.1K

Ticker ADGI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 108,831,000
Market Cap $505M
Description
Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatmen...

Get notified when there are updates to the investment portfolio of American International Group, Inc., based on Form 13F filings with the SEC.

Stay updated on American International Group, Inc. with notifications on news.